$5.29 Million in Sales Expected for Bicycle Therapeutics plc (NASDAQ:BCYC) This Quarter

Equities analysts forecast that Bicycle Therapeutics plc (NASDAQ:BCYC) will post sales of $5.29 million for the current fiscal quarter, Zacks Investment Research reports. Six analysts have issued estimates for Bicycle Therapeutics’ earnings, with estimates ranging from $1.50 million to $17.60 million. Bicycle Therapeutics reported sales of $3.84 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 37.8%. The company is scheduled to announce its next earnings report on Thursday, November 4th.

On average, analysts expect that Bicycle Therapeutics will report full-year sales of $12.82 million for the current financial year, with estimates ranging from $6.59 million to $23.80 million. For the next fiscal year, analysts forecast that the business will report sales of $19.50 million, with estimates ranging from $7.14 million to $67.00 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that cover Bicycle Therapeutics.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its quarterly earnings results on Thursday, August 5th. The company reported ($0.74) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.71) by ($0.03). Bicycle Therapeutics had a negative return on equity of 50.43% and a negative net margin of 546.62%. The business had revenue of $1.79 million for the quarter, compared to analysts’ expectations of $2.51 million.

A number of equities research analysts recently commented on BCYC shares. JMP Securities lifted their target price on Bicycle Therapeutics from $53.00 to $85.00 and gave the stock an “outperform” rating in a report on Thursday. Canaccord Genuity lifted their target price on Bicycle Therapeutics from $40.00 to $60.00 and gave the stock a “buy” rating in a report on Monday. Oppenheimer lifted their target price on Bicycle Therapeutics from $47.00 to $65.00 and gave the stock an “outperform” rating in a report on Friday, October 8th. Roth Capital boosted their price target on Bicycle Therapeutics from $35.00 to $65.00 and gave the company a “buy” rating in a report on Thursday, October 7th. Finally, Zacks Investment Research downgraded Bicycle Therapeutics from a “buy” rating to a “sell” rating in a report on Tuesday. One equities research analyst has rated the stock with a sell rating and eight have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $67.22.

In other Bicycle Therapeutics news, CEO Kevin Lee sold 5,000 shares of the company’s stock in a transaction on Monday, October 11th. The stock was sold at an average price of $53.88, for a total value of $269,400.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Lee Kalowski sold 12,500 shares of the company’s stock in a transaction on Thursday, July 29th. The shares were sold at an average price of $31.51, for a total value of $393,875.00. Following the completion of the sale, the chief financial officer now owns 12,500 shares of the company’s stock, valued at $393,875. The disclosure for this sale can be found here. Insiders sold 51,474 shares of company stock valued at $1,859,850 over the last 90 days. Company insiders own 17.90% of the company’s stock.

Institutional investors have recently made changes to their positions in the company. WealthShield Partners LLC acquired a new position in shares of Bicycle Therapeutics in the 2nd quarter valued at $27,000. Citigroup Inc. lifted its stake in shares of Bicycle Therapeutics by 107.8% in the 2nd quarter. Citigroup Inc. now owns 1,066 shares of the company’s stock valued at $32,000 after purchasing an additional 553 shares during the last quarter. JPMorgan Chase & Co. acquired a new position in shares of Bicycle Therapeutics in the 1st quarter valued at $39,000. Personal CFO Solutions LLC acquired a new position in Bicycle Therapeutics during the 2nd quarter worth about $221,000. Finally, Geode Capital Management LLC acquired a new position in Bicycle Therapeutics during the 2nd quarter worth about $227,000. 48.67% of the stock is currently owned by institutional investors and hedge funds.

Shares of BCYC stock traded up $3.46 during trading hours on Monday, reaching $59.84. 27,385 shares of the company’s stock were exchanged, compared to its average volume of 468,441. Bicycle Therapeutics has a 1 year low of $17.68 and a 1 year high of $56.81. The stock has a market cap of $1.53 billion, a PE ratio of -19.99 and a beta of -0.42. The company has a current ratio of 9.36, a quick ratio of 9.36 and a debt-to-equity ratio of 0.21. The stock’s fifty day moving average price is $38.74 and its two-hundred day moving average price is $33.55.

About Bicycle Therapeutics

Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display screening platform to identify bicycles.

Read More: What is the cash asset ratio?

Get a free copy of the Zacks research report on Bicycle Therapeutics (BCYC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bicycle Therapeutics (NASDAQ:BCYC)

Receive News & Ratings for Bicycle Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicycle Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.